摘要
[目的]研究P鄄gp、HSP70、GST鄄π在乳腺癌中的表达及临床意义。[方法]根治乳腺癌库存石蜡包埋且随访资料完整组织60例行SP法免疫组化法染色。[结果]P鄄gp阳性率为37.33%,P鄄gp阳性率随乳腺癌组织分化程度下降而升高(P<0.01)。与10年生存率呈负相关(P<0.05),与年龄、临床分期、淋巴结转移数无明显相关(P>0.05)。HSP70阳性率为33.33%,HSP70阳性率随乳腺癌组织分化程度下降而升高(P<0.01)。与10年生存率呈负相关(P<0.05),与年龄、临床分期、淋巴结转移数无明显相关(P>0.05)。GST鄄π阳性表达率高达56.67%。在乳腺癌临床Ⅲ、Ⅳ期中其阳性表达率高达75%、66.67%,与临床Ⅰ、Ⅱ期相比差异有显著性(P<0.05)。其阳性表达率与淋巴结转移数相关(P<0.05),与年龄、组织分化程度、10年生存率无明显相关(P>0.05)。MDR1和GST鄄π存在明显的共表达。[结论]判断临床耐药时应同时检测MDR1、HSP70和GST鄄π三个耐药相关基因的表达,才能得到较全面的耐药信息,并且要把MDR1当作主要方面来对待。
To explore expression of P-gp, HSP70 and GST-π,and to evaluate their clinical significance in breast cancer. Routine section preparation from 60 cases with breast cancer patients with perfect follow-up data were measured with SP Immunohistochemistry method to evaluate the clinical significance of P-gp, HSP70 and GST-π. The expression rate of MDR1 was 37.33%.The positive expression rate of MDR1 was increased along with malignant degree(P<0.01) and decrease along with 10-year survival rate(P<0.05). The expression rate of MDR1 was not related to age, positive lymph node number and clinical tumor stage(P>0.05). The expression rate of HSP70 was 33.33%. The positive expression rate of HSP70 was increased along with malignant degree(P<0.01) and decrease along with 10-year survival rate(P<0.05). The expression rate of HSP70 was not related to age, positive lymph node number and clinical stage(P>0.05). The expression rate of GST-π was 56.67%. The expression of GST-π was correlated with clinical stage(Ⅳ,Ⅲ>Ⅱ,Ⅰ) and positive lymph node number. The expression rate of GST-π was not related to age,malignant degree positive lymph node number and 10-year survival rate(P>0.05). Co-expression of P-gp and GST-π in breast cancer was found in evidence. [Conclusion] A combined analysis of the expression of P-gp, HSP70 and GST-π in breast cancer may contribute to the selection of drug in chemotherapy. Among them the expression of P-gp is of special importance.
出处
《肿瘤学杂志》
CAS
2004年第3期136-138,共3页
Journal of Chinese Oncology
